Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis
暂无分享,去创建一个
[1] D. Dingli,et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains , 2018, Leukemia.
[2] H. Goldschmidt,et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. , 2017, Blood.
[3] P. Milani,et al. The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic , 2017, American journal of hematology.
[4] P. Neri,et al. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? , 2017, Bone Marrow Transplantation.
[5] D. Seldin,et al. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[6] A. Foli,et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. , 2015, Blood.
[7] D. Seldin,et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. , 2015, Blood.
[8] A. Foli,et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.
[9] G. Doros,et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement , 2014, Bone Marrow Transplantation.
[10] D. Seldin,et al. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Falk,et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.
[12] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Therneau,et al. Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. , 2011, Clinical chemistry.
[15] J. Tate,et al. Quantitative serum free light chain assay--analytical issues. , 2009, The Clinical biochemist. Reviews.
[16] G. Merlini,et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. , 2009, Clinical chemistry.
[17] M Boccadoro,et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders , 2009, Leukemia.
[18] M. Oken,et al. Appraisal of immunoglobulin free light chain as a marker of response. , 2008, Blood.
[19] H. Goldschmidt,et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis , 2008, Haematologica.
[20] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[21] R. Falk,et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis , 2005, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.